Abstracts tagged "gout"

Abstract Number: 888 • 2014 ACR/ARHP Annual Meeting
Annual Medical Care Expenditures Among US Adults with Gout, 2005 – 2011
Miriam G. Cisternas¹, Louise Murphy², David J. Pasta³, Edward H. Yelin⁴ and Charles Helmick⁵, ¹MGC Data Services, Carlsbad, CA, ²Division of Population Health, Centers for Disease Control and Prevention, Atlanta, GA, ³DMA Corporation, Palo Alto, CA, ⁴Arthritis Research Group, University of California, San Francisco, San Francisco, CA, ⁵Arthritis Program, Centers for Disease Control and Prevention, Atlanta, GA
Background/Purpose: Costs associated with gout are of growing interest due to its increasing prevalence, but quantifying those costs has been hampered by its co-occurrence with…
Abstract Number: 827 • 2014 ACR/ARHP Annual Meeting
Gout and the Risk of Alzheimer’s Disease: A Population-Based Cohort Study
Na Lu¹, Yuqing Zhang¹, Alberto Ascherio², Miguel Hernan², Tuhina Neogi¹, Maureen Dubreuil^3,4 and Hyon K. Choi⁵, ¹Boston University School of Medicine, Boston, MA, ²Epidemiology, Harvard School of Public Health, Boston, MA, ³Rheumatology, Boston University Medical Center, Boston, MA, ⁴Rheumatology, Boston VA HealthCare System, Boston, MA, ⁵Division of Rheumatology, Allergy, and Immunology Massachusetts General Hospital, Harvard Medical School, Boston, MA
Background/Purpose: While gout is associated with cardiovascular (CV)-metabolic comorbidities and their sequelae, uric acid's anti-oxidant effects may have neuroprotective benefits. Several studies have found an…
Abstract Number: 250 • 2014 ACR/ARHP Annual Meeting
Early Gout Pain Response at 28 Hours Predicts Response at 5 Days on Both Patient Pain and Physician Global Assessment
Paul M. Peloso¹, Ted R. Mikuls², Brian W. Coburn³, H. Ralph Schumacher Jr.⁴, Davis F. Gates¹, Zoran Popmihajlov¹, Walter L. Straus¹ and R. Andrew Moore⁵, ¹Merck & Co., Inc., Whitehouse Station, NJ, ²Omaha VA Medical Center and University of Nebraska Medical Center, Omaha, NE, ³Omaha VA and University of Nebraska Medical Center, Omaha, NE, USA, Omaha, NE, ⁴Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, ⁵University of Oxford, Nuffield Division of Anaesthetics, Oxford, England
Background/Purpose This post-hoc analysis from a randomized trial1in acute gout asked whether early pain responses predict subsequent pain and investigator global responses. Methods Patient assessment…
Abstract Number: 1993 • 2013 ACR/ARHP Annual Meeting
Geographic Variations Of Gout Epidemiology In The United Kingdom: A Nationwide Population Study
Chang-Fu Kuo^1,2, Michael Doherty³, Matthew J. Grainge⁴ and Weiya Zhang¹, ¹Academic Rheumatology, School of Clinical Sciences, University of Nottingham, Nottingham, United Kingdom, ²Division of Rheumatology, Allergy and Immunology, Chang Gung Memorial Hospital, Taipei, Taiwan, ³Academic Rheumatology, University of Nottingham, Nottingham, United Kingdom, ⁴Division of Epidemiology and Public Health, School of Community Health Sciences,, University of Nottingham, Nottingham, United Kingdom
Background/Purpose: To examine geographic variations of gout prevalence, incidence and management in the United Kingdom. Methods: We used the Clinical Practice Research Data-link (CPRD) to…
Abstract Number: 1181 • 2013 ACR/ARHP Annual Meeting
The Effect Of Uric Acid Lowering Therapy In Preventing Comorbidity and Acute Attack Of Gout; A Retrospective Study
Kowoon Joo¹, Won Park¹, Seong-Ryul Kwon¹, Mie-Jin Lim¹, Kyong-Hee Jung¹, Hoyeon Joo¹ and Sung-Soo Kim², ¹Division of Rheumatology, Department of Internal Medicine, Inha University Hospital, Incheon, South Korea, ²Division of Rheumatology, Department of Internal Medicine, Ulsan Univ College of Medicine and Gangneung Asan Hospital, Gangneung, South Korea
Background/Purpose: We evaluated the effect of uric acid lowering therapy (ULT) in reducing the new development of comorbidities and the frequency of acute attacks…
Abstract Number: 212 • 2013 ACR/ARHP Annual Meeting
Dual-Energy Computed Tomography for Monitoring of Urate Deposition in Tophaceous Gout: A Prospective Longitudinal Study Examining Sensitivity to Change
Ashwin Rajan¹, Opetaia Aati², Ramanamma Kalluru³, Gregory Gamble², Anne Horne², Anthony Doyle¹, Fiona M. McQueen⁴ and Nicola Dalbeth⁵, ¹University of Auckland, Auckland, New Zealand, ²Department of Medicine, University of Auckland, Auckland, New Zealand, ³Department of Rheumatology, Auckland District Health Board, Auckland, New Zealand, ⁴Molecular Medicine and Pathology, University of Auckland, Auckland, New Zealand, ⁵Medicine, University of Auckland, Auckland, New Zealand
Background/Purpose: Dual-energy computed tomography (DECT) is an advanced imaging method with potential for monitoring urate deposition in patients with gout. The aim of this prospective…
Abstract Number: 1996 • 2013 ACR/ARHP Annual Meeting
Racial/Ethnicity Differences In Health-Related Quality Of Life (HRQOL), Functional Ability and Health Care Utilization In Gout Patients
Aseem Bharat¹, Jasvinder A. Singh^2,3, Puja Khanna⁴, Cleopatra Aquino-Beaton⁵, Jay E. Persselin⁶, Erin Duffy⁷, David Elashoff⁸ and Dinesh Khanna⁹, ¹Medicine/Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ²Rheumatology, Birmingham VA, Birmingham, AL, ³Department of Medicine, University of Alabama, Tuscaloosa, AL, ⁴Division of Rheumatology, University of Michigan Medical Center, Ann Arbor, MI, ⁵Rheumatology, VA Greater Los Angeles Healthcare System, Los Angeles, CA, ⁶Medicine W-111J Div of Rheum, VA Greater Los Angeles Healthcare System, Los Angeles, CA, ⁷Medicine, University of California Los Angeles, Los Angeles, CA, ⁸Medicine- Statistic Core, UCLA Department of Medicine Statistics Core, Los Angeles, CA, ⁹University of Michigan, Ann Arbor, MI
Background/Purpose: Due to limited/no data for race/ethnicity, our objective was to assess whether HRQOL functional ability and health care utilization in gout patients differs by…
Abstract Number: 1183 • 2013 ACR/ARHP Annual Meeting
The Treatment Of Gout In Relation To The 2012 Uric Acid Target Guidelines In The US Population
Stephen Juraschek¹, Lara Kovell², Edgar Miller III² and Allan C. Gelber³, ¹Department of Medicine, Johns Hopkins University, Baltimore, MD, ²Medicine, Johns Hopkins University, Baltimore, MD, ³Medicine/ Rheumatology, Johns Hopkins University, Baltimore, MD
The Treatment of Gout in Relation to the 2012 Uric Acid Target Guidelines in the US Population Background/Purpose: Gout is a debilitating form of arthritis mediated…
Abstract Number: 213 • 2013 ACR/ARHP Annual Meeting
Digital Tomosynthesis for Measurement of Bone Erosion in Gout: Comparison With Computed Tomography
Nicola Dalbeth¹, Anthony Doyle², Mark Roger³, Angela Gao⁴ and Fiona M. McQueen⁵, ¹Medicine, University of Auckland, Auckland, New Zealand, ²University of Auckland, Auckland, New Zealand, ³Department of Radiology, Auckland District Health Board, Auckland, New Zealand, ⁴Radiology, Auckland District Health Board, Auckland, New Zealand, ⁵Molecular Medicine and Pathology, University of Auckland, Auckland, New Zealand
Background/Purpose: Digital tomosynthesis is a recently developed imaging method in which multiple projected images obtained at different angles are collected with a digital detector. These…
Abstract Number: 2001 • 2013 ACR/ARHP Annual Meeting
Kaiser Permanent Pyramid In Patients With Gout: The Most Severe Gout Is Associated To The Most Complex Patients
Fernando Perez-Ruiz^1,2, Ana M. Herrero-Beites^1,3 and Amaya Martinez-Galarza^4,5, ¹BioCruces Health Research Institute, Baracaldo, Spain, ²Servicio de Reumatologia, Hospital Universitario Cruces, Baracaldo, Spain, ³Physical Medicine Division, Hospital de Gorliz, Gorliz, Spain, ⁴Clinical Investigation Unit, Hospital Universitario Cruces, Baracaldo, Spain, ⁵BioCruces Health Institute, Baracaldo, Spain
Background/Purpose: gout is well known to be associated with comorbid conditions; the Kaiser Permanente Pyramid (KPP) identify high risk people (two higher strata) in the…
Abstract Number: 1184 • 2013 ACR/ARHP Annual Meeting
High Mobility Group Box 1 Plays a Role In Gouty Arthritis
Kiwon Moon¹, Jinhyun Kim² and Yun Jong Lee³, ¹Internal medicine,, Kangwon National University Hospital, Chuncheon city, Kangwon province, South Korea, ²Internal medicine, Chungnam National University School of Medicine, Daejeon, South Korea, ³Division of Rheumatology, Department of Internal Medicine,Seoul National University Bundang Hospital, Seongnam, South Korea
Background/Purpose: High mobility group box 1 (HMGB1) is a crucial cytokine that mediated the response to infection, injury and inflammation. It is recently discovered that…
Abstract Number: 180 • 2013 ACR/ARHP Annual Meeting
Familial Aggregation Of Female Premenopausal Gout –Monogenic, Polygenic Or Clinical Coincidence?
Bingqing Zhang¹, Shufen Liu², Nuo Si³, Yun Zhang^2,4 and Xuejun Zeng⁵, ¹Peking Union Medical College, Beijing, China, ²Peking Union Medical College Hospital, Beijing, China, ³Chinese Academy of Medical Science & Peking Union Medical College, Beijing, China, ⁴Peking Union Medical College Hospital, Chinese Academy of Medical Science & Peking Union Medical College, Beijing, China, ⁵Medicine, Peking Union Medical College Hospital, Beijing, China
Background/Purpose: Primary gout is a multifactorial disease, in which genetic background and environmental factors interact with each other. Genetic predisposition is particularly prominent in those…
Abstract Number: 2007 • 2013 ACR/ARHP Annual Meeting
Using Natural Language Processing and Machine Learning To Identify Gout Flares From Electronic Clinical Notes
Chengyi Zheng¹, Nazia Rashid², T. Craig Cheetham³, Yi-Lin Wu³ and Gerald D. Levy⁴, ¹Department of Research and Evaluation, Kaiser Permanente Southern California, Pasadena, CA, ²Pharmacy Analytical Services, Kaiser Permanente Southern California, Downey, CA, ³Pharmacy Analytical Services, Kaiser Permanente, Downey, CA, ⁴Int Med/Rheumatology, Southern California Permanente Medical Group, Downey, CA
Background/Purpose: Gout flares are the most common manifestation of gout. Gout flares are not well documented by diagnosis codes and are not adequately captured when…
Abstract Number: 1185 • 2013 ACR/ARHP Annual Meeting
More Than One-Third Of Patients Reach Serum Urate Target and Continue To Report Multiple Flares
Dinesh Khanna¹, Puja Khanna², Chris Storgard³, Scott Baumgartner⁴ and Robert Morlock⁵, ¹Division of Rheumatology, University of Michigan, Ann Arbor, MI, ²Division of Rheumatology, University of Michigan Medical Center, Ann Arbor, MI, ³4939 Directors Place, Ardea Bioscience, San Diego, CA, ⁴Ardea Biosciences, San Diego, CA, ⁵Ardea Bioscience, San Diego, CA
Background/Purpose: Gout is a common inflammatory arthritis, and its worldwide prevalence is increasing. EULAR and ACR guidelines recommend a target serum urate (sUA) ≤6 mg/dL.…
Abstract Number: 1984 • 2013 ACR/ARHP Annual Meeting
Impact Of Educational Attainment On Health-Related Quality Of Life and Healthcare Utilization Among Veterans With Gout
Cleopatra Aquino-Beaton¹, Jay E. Persselin², Ari Weinreb¹, Meika A Fang¹, Jasvinder A. Singh^3,4, Erin Duffy⁵, David Elashoff⁶, Puja Khanna^7,8 and Dinesh Khanna⁹, ¹Rheumatology, VA Greater Los Angeles Healthcare System, Los Angeles, CA, ²Medicine W-111J Div of Rheum, VA Greater Los Angeles Healthcare System, Los Angeles, CA, ³Department of Medicine, University of Alabama, Tuscaloosa, AL, ⁴Rheumatology, Birmingham VA, Birmingham, AL, ⁵Medicine, University of California Los Angeles, Los Angeles, CA, ⁶Medicine- Statistic Core, UCLA Department of Medicine Statistics Core, Los Angeles, CA, ⁷Division of Rheumatology/Dept. of Internal Medicine, University of Michigan Medical Center, Ann Arbor, MI, ⁸Rheumatology, Ann Arbor VA, Ann Arbor, MI, ⁹Division of Rheumatology, University of Michigan Medical Center, Ann Arbor, MI
Background/Purpose: Gout is a debilitating, chronic disease that requires ongoing treatment and effective self-management. Successful gout treatment depends on multiple factors, including educational attainment. Adequate…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.